Occam Recruits Head of BD for Latent Labs
This fall, Occam placed Martha Carruthers as Head of Business Development for Latent Labs. Martha brings nearly two decades of commercial strategy and corporate development experience within big pharma and biotech. She previously served as Chief Business Officer at Avagen Therapeutics and led corporate development at Pear Therapeutics. Earlier in her career, she led marketing efforts for Janssen's Healthcare Innovation Group.
Martha holds an HBSc in Human Kinetics from the University of Guelph and an MBA from the University of Oxford.
About Latent Labs
Latent Labs is an AI-driven biotechnology company developing foundation models to make biology programmable. The company innovates on and applies generative AI technologies to enable biotechnology and pharmaceutical companies to computationally create new molecules for a range of therapeutic, industrial, and environmental uses. Founded by Dr. Simon Kohl, a former DeepMind researcher and key contributor to the AlphaFold project, the company is backed by leading investors including Radical Ventures, Sofinnova Partners, 8VC, Kindred Capital, Pillar VC, Isomer and Flying Fish.
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.